Opko Health, Inc. · NASDAQ:OPK

Opko Health — Corporate Update (June 2014)

11 slides from Opko Health's corporate update, Jun 17, 2014

  1. Slide 1: Welcome to FineTech Pharmaceutical

    Exhibit 99.3 Welcome to FineTech Pharmaceutical

  2. Slide 2: FineTech overview: specialty APIs and organic synthesis

    • Manufactures high value, low volume specialty APIs and provides organic synthesis capabilities for OPKO's drug development projects • Operates in a 35,000 sq. ft. sate of the art, FDA approved facility with top of the line equipment • Employs a highly motivated, experienced and creative team of 40

  3. Slide 3: What is the SECRET of this exceptionally high profitability?

    What is the SECRET of this exceptionally high profitability? QUESTION:

  4. Slide 4: Answer: Perfect Quality Mix

    • Facility/Equipment • Science/Technology • Ability to Create Intellectual Property • Regulatory Affairs • Effective Management of a Creative Team • Commercial Acumen in choosing the right product at the right time ANSWER: PERFECT QUALITY MIX

  5. Slide 5: This Perfect Quality Mix enables a customer to be first generic

    This PERFECT QUALITY MIX enables a customer to be the first generic company to launch a specialty product with complex chemistry or patent challenges. In such cases companies are prepared to pay substantial premiums and commit to long- term agreements.

  6. Slide 6: Cabergoline, Latanoprost, Nabilone, Travoprost, Bimatoprost

    Cabergoline Latanoprost Nabilone Travoprost Bimatoprost

  7. Slide 7: Development compounds: SR-3306, C-34, disaccharides, vitamin D derivatives

    SR-3306 – treatment of Parkinson disease C-34 – anti-tumor and immune-stimulating activity Disaccharides – treatment of asthma Different derivatives of vitamin D and CYP -24 inhibitors

  8. Slide 8: Slide 8

  9. Slide 9: Slide 9

  10. Slide 10: Slide 10

  11. Slide 11: Slide 11

OPKO Health — Corporate Update (June 2014) on 6ix